Gilead Sciences Inc., first to market with a new hepatitis C drug, now faces a bulked-up rival in Merck & Co., which paid the highest premium ever in a health- care deal to gain an experimental product that’s similar.
Myriad Genetics Inc. Chief Executive Officer Pete Meldrum says his lab test to pinpoint tumors with a specific genetic mutation could have helped Sanofi-Aventis SA succeed if it had been used in a study of a drug that failed in breast cancer.
Myriad Genetics Inc. , the maker of genetic tests that predict breast cancer risk, rose to its highest price in five months in Nasdaq trading after an analyst upgraded the company and said it may be an acquisition target.
InterMune Inc., the developer of a medicine for idiopathic pulmonary fibrosis, dropped the most in almost two years as investors grew concerned about competition from drugmaker Boehringer Ingelheim GmbH.
BioMarin Pharmaceutical Inc., with five drugs in clinical trials, is seeking to buy smaller companies to expand its pipeline for treatment of rare diseases, not be acquired itself, Chief Executive Officer Jean-Jacques Bienaime said in an interview.
Amgen Inc., the world’s largest biotechnology company, rose the most in eight months after second-quarter profit topped analysts’ estimates on increased demand for its rheumatoid arthritis and bone drugs and the company raised its 2012 forecast.